The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study

被引:1
作者
Aldekhail, N. M. [1 ,5 ]
Morrison, D. S. [2 ]
Khojah, H. [3 ]
Sloan, B. [2 ]
McLoone, P. [2 ]
MacNaughton, S. [4 ]
Shearer, R. [4 ]
Logue, J. [1 ]
机构
[1] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[3] Univ Strathclyde, Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[4] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland
[5] Secur Forces Hosp Programme, Riyadh, Saudi Arabia
关键词
GLYCEMIC CONTROL; GLUCOSE CONTROL; TYPE-2; METFORMIN; ROSIGLITAZONE; PIOGLITAZONE; SULFONYLUREA; HYPOGLYCEMIA; PREDICTORS; MELLITUS;
D O I
10.1111/dme.14093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To compare weight change in a lifestyle-based weight management programme between participants taking weight-gaining, weight-neutral/loss and mixed diabetes medications. Methods Electronic health records for individuals (>= 18 years) with Type 2 diabetes who had been referred to a non-surgical weight management programme between February 2008 and May 2014 were studied. Diabetes medications were classified into three categories based on their effect on body weight. In this intervention cohort study, weight change was calculated for participants attending two or more sessions. Results All 998 individuals who took oral diabetes medications and attended two or more sessions of weight management were included. Some 59.5% of participants were women, and participants had a mean BMI of 41.1 kg/m(2) (women) and 40.2 kg/m(2) (men). Of the diabetes medication combinations prescribed, 46.0% were weight-neutral/loss, 41.3% mixed and 12.7% weight-gaining. The mean weight change for participants on weight-gaining and weight-neutral/loss diabetes medications respectively was -2.5 kg [95% confidence interval (CI) -3.2 to -1.8) and -3.3 kg (95% CI -3.8 to -2.9) (P = 0.05) for those attending two or more sessions (n = 998). Compared with those prescribed weight-neutral medications, participants prescribed weight-gaining medication lost 0.86 kg less (95% CI 0.02 to 1.7; P = 0.045) in a model adjusted for age, sex, BMI and socio-economic status. Conclusions Participants on weight-neutral/loss diabetes medications had a greater absolute weight loss within a weight management intervention compared with those on weight-gaining medications. Diabetes medications should be reviewed ahead of planned weight-loss interventions to help ensure maximal effectiveness of the intervention.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 28 条
[2]  
[Anonymous], EATW PLAT
[3]   Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].
Astrup, A. ;
Carraro, R. ;
Finer, N. ;
Harper, A. ;
Kunesova, M. ;
Lean, M. E. J. ;
Niskanen, L. ;
Rasmussen, M. F. ;
Rissanen, A. ;
Rossner, S. ;
Savolainen, M. J. ;
Van Gaal, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :843-854
[4]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[5]   Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight [J].
Bonora, E. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 :19-28
[6]   Effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: A comparison of interventional and non-interventional outcomes at 3 years [J].
Botha, Shani ;
Forde, Lorna ;
MacNaughton, Sheila ;
Shearer, Ross ;
Lindsay, Robert ;
Sattar, Naveed ;
Morrison, David ;
Welsh, Paul ;
Logue, Jennifer .
DIABETES OBESITY & METABOLISM, 2018, 20 (04) :879-888
[7]  
British National Formulary, ANT DRUGS
[8]  
Diabetes UK, 2017, TOP 10 RES PRIOR TYP
[9]   Weight loss from three commercial providers of NHS primary care slimming on referral in North Somerset: service evaluation [J].
Dixon, Karin J. L. ;
Shcherba, Sandra ;
Kipping, Ruth R. .
JOURNAL OF PUBLIC HEALTH, 2012, 34 (04) :555-561
[10]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289